Avalo Therapeutics Inc (AVTX) - Total Assets
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) holds total assets worth $125.10 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AVTX total equity for net asset value and shareholders' equity analysis.
Avalo Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Avalo Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Avalo Therapeutics Inc's total assets of $125.10 Million consist of 92.1% current assets and 7.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.3% |
| Accounts Receivable | $611.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $10.50 Million | 7.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Avalo Therapeutics Inc (AVTX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avalo Therapeutics Inc's current assets represent 92.1% of total assets in 2024, a decrease from 99.3% in 2012.
- Cash Position: Cash and equivalents constituted 89.3% of total assets in 2024, down from 95.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 7.0% of total assets.
Avalo Therapeutics Inc Competitors by Total Assets
Key competitors of Avalo Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Avalo Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.28 | 1.42 | 1.71 |
| Quick Ratio | 14.28 | 1.42 | 1.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $105.87 Million | $25.47 Million | $10.78 Million |
Avalo Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Avalo Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.48 |
| Latest Market Cap to Assets Ratio | 1.68 |
| Asset Growth Rate (YoY) | 618.0% |
| Total Assets | $150.73 Million |
| Market Capitalization | $253.81 Million USD |
Valuation Analysis
Above Book Valuation: The market values Avalo Therapeutics Inc's assets above their book value (1.68x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Avalo Therapeutics Inc's assets grew by 618.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Avalo Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $150.73 Million | +618.01% |
| 2023-12-31 | $20.99 Million | -37.08% |
| 2022-12-31 | $33.37 Million | -58.40% |
| 2021-12-31 | $80.21 Million | +83.33% |
| 2020-12-31 | $43.76 Million | +21.17% |
| 2019-12-31 | $36.11 Million | -48.60% |
| 2018-12-31 | $70.25 Million | +62.90% |
| 2017-12-31 | $43.12 Million | +647.51% |
| 2016-12-31 | $5.77 Million | -73.36% |
| 2015-12-31 | $21.66 Million | +75.84% |
| 2014-12-31 | $12.32 Million | +142.67% |
| 2013-12-31 | $5.08 Million | -49.34% |
| 2012-12-31 | $10.02 Million | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more